It has been reported that Gal-3 enhanced the protein expression of immune checkpoint ligand PD-L1 in lung cancer cells in vitro by increasing STAT3 phosphorylation, while a Gal-3 inhibitor (GB1107) decreased both PD-L1 expression and STAT3 phosphorylation in these cells. This evidence concerns the gene LGALS3 and lung carcinoma.